Eduardo Arzt

Eduardo Arzt

Auto-generated profile, based on publicly available information

Eduardo Arzt

Instituto de Investigación en Biomedicina de Buenos Aires (IBioBA), CONICET – Partner Institute of the Max Planck Society, Buenos Aires, Argentina

Research Focus & Metrics

Academic Career Length

32Years (1995-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
16 July 2024 in Aging Cell
Verified
Journal Article
Open access
FHFlorencia Herbstein
Florencia Herbstein
MSMelanie Sapochnik
Melanie Sapochnik
AAAlejandra Attorresi
Alejandra Attorresi
CPCora Pollak
Cora Pollak
SSSergio Senin
Sergio Senin
EAEduardo Arzt
Eduardo Arzt
Senescent cells produce a Senescence‐Associated Secretory Phenotype (SASP) that involves factors with diverse and sometimes contradictory activities. One key SASP factor, interleukin‐6 (IL‐6), has the potential to amplify cellular senescence in the SASP‐producing cells in an autocrine action, while simultaneously inducing proliferation in the neighboring cells. The underlying mechanisms for the contrasting actions remain unclear. We found that the senescence action does not involve IL‐6 secretion nor the interaction with the receptor expressed in the membrane but is amplified through an intracrine mechanism. IL‐6 sustains intracrine senescence interacting with the intracellular IL‐6 receptor located in anterograde traffic specialized structures, with cytosolic DNA, cGAS‐STING, and NFκB activation. This pathway triggered by intracellular IL‐6 significantly contributes to cell‐autonomous induction of senescence and impacts in tumor growth control. Inactivation of IL‐6 in somatotrophic senescent cells transforms them into strongly tumorigenic in NOD/SCID mice, while re‐expression of IL‐6 restores senescence control of tumor growth. The intracrine senescent IL‐6 pathway is further evidenced in three human cellular models of therapy‐induced senescence. The compartmentalization of the intracellular signaling, in contrast to the paracrine tumorigenic action, provides a pathway for IL‐6 to sustain cell‐autonomous senescent cells, driving the SASP, and opens new avenues for clinical consideration to senescence‐based therapies.

27 October 2017 in The Journal of Neuroscience
Verified
Journal Article
Open access
PDF file
MMMichael W. Metzger
Michael W. Metzger
SWSandra M. Walser
Sandra M. Walser
NDNina Dedic
Nina Dedic
FAFernando Aprile-Garcia
Fernando Aprile-Garcia
VJVladimira Jakubcakova
Vladimira Jakubcakova
Maximilian DeussingMaximilian Deussing
Maximilian Deussing
A single nucleotide polymorphism substitution from glutamine (Gln, Q) to arginine (Arg, R) at codon 460 of the purinergic P2X7 receptor (P2X7R) has repeatedly been associated with mood disorders. The P2X7R-Gln460Arg variant per se is not compromised in its function. However, heterologous expression of P2X7R-Gln460Arg together with wild-type P2X7R has recently been demonstrated to impair receptor function. Here we show that this also applies to humanized mice coexpressing both human P2X7R variants. Primary hippocampal cells derived from heterozygous mice showed an attenuated calcium uptake upon agonist stimulation. While humanized mice were unaffected in their behavioral repertoire under basal housing conditions, mice that harbor both P2X7R variants showed alterations in their sleep quality resembling signs of a prodromal disease stage. Also healthy heterozygous human subjects showed mild changes in sleep parameters. These results indicate that heterozygosity for the wild-type P2X7R and its mood disorder-associated variant P2X7R-Gln460Arg represents a genetic risk factor, which is potentially able to convey susceptibility to mood disorders.SIGNIFICANCE STATEMENTDepression and bipolar disorder are the most common mood disorders. The P2X7 receptor (P2X7R) regulates many cellular functions. Its polymorphic variant Gln460Arg has repeatedly been associated with mood disorders. Genetically engineered mice, with human P2X7R, revealed that heterozygous mice (i.e., they coexpress the disease-associated Gln460Arg variant together with its normal version) have impaired receptor function and showed sleep disturbances. Human participants with the heterozygote genotype also had subtle alterations in their sleep profile. Our findings suggest that altered P2X7R function in heterozygote individuals disturbs sleep and might increase the risk for developing mood disorders.

24 November 2016 in Oncotarget
Verified
Journal Article
Open access
PDF file
MSMelanie Sapochnik
Melanie Sapochnik
MHMariana R. Haedo
Mariana R. Haedo
MFMariana Fuertes
Mariana Fuertes
PAPablo Ajler
Pablo Ajler
GCGuillermo Carrizo
Guillermo Carrizo
EAEduardo Arzt
Eduardo Arzt
Autocrine IL-6 mediates pituitary tumor senescence

1 May 2017 in Journal of Molecular Endocrinology
Verified
Journal Article
Open access
PDF file
MSMelanie Sapochnik
Melanie Sapochnik
MFMariana Fuertes
Mariana Fuertes
EAEduardo Arzt
Eduardo Arzt
IL-6 is a pleiotropic cytokine with multiple pathophysiological functions. As a key factor of the senescence secretome, it can not only promote tumorigenesis and cell proliferation but also exert tumor suppressive functions, depending on the cellular context. IL-6, as do other cytokines, plays important roles in the function, growth and neuroendocrine responses of the anterior pituitary gland. The multiple actions of IL-6 on normal and adenomatous pituitary function, cell proliferation, angiogenesis and extracellular matrix remodeling indicate its importance in the regulation of the anterior pituitary. Pituitary tumors are mostly benign adenomas with low mitotic index and rarely became malignant. Premature senescence occurs in slow-growing benign tumors, like pituitary adenomas. The dual role of IL-6 in senescence and tumorigenesis is well represented in pituitary tumor development, as it has been demonstrated that effects of paracrine IL-6 may allow initial pituitary cell growth, whereas autocrine IL-6 in the same tumor triggers senescence and restrains aggressive growth and malignant transformation. IL-6 is instrumental in promotion and maintenance of the senescence program in pituitary adenomas.

13 May 2016 in Cell Death & Differentiation
Verified
Journal Article
Closed access
MAM Antunica-Noguerol
M Antunica-Noguerol
MBM L Budziñski
M L Budziñski
JDJ Druker
J Druker
NGNils Gassen
Nils Gassen
MSM C Sokn
M C Sokn
EAE Arzt
E Arzt

30 December 2015 in Biochemical Genetics
Verified
Journal Article
Closed access
PDF file
MSMelanie Sapochnik
Melanie Sapochnik
LNLeandro Eduardo Nieto
Leandro Eduardo Nieto
MFMariana Fuertes
Mariana Fuertes
EAEduardo Arzt
Eduardo Arzt